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Abstract: Rationale: Mutation in the alpha1 antitrypsin (AAT) gene leads to low circulating levels
of AAT, which is associated with several disease processes including pulmonary emphysema.
The standard of care relies on substitution with plasma-purified AAT. We studied a novel approach to
obtain sustained therapeutic levels of circulating AAT using nonviral in vivo electroporation-mediated
gene transfer to the liver. Methods: In vivo intrahepatic electroporation-mediated human AAT gene
transfer was performed in C57 Bl/6J mice carrying a genetic deficiency of murine AAT (pallid
mice) and suffering from pulmonary emphysema. The animals were evaluated for lung function
using flexiVent and detailed stereological assessments. Lung neutrophilic burden was assessed.
Results: Pallid mice showed morphologically detectable pulmonary emphysema. Thirty days
after in vivo electroporation-mediated gene transfer directly aimed at the liver, circulating human
AAT was elevated and lung function was significantly improved compared to non-treated pallid
mice. Stereological analysis revealed a reduction in pulmonary emphysema. Conclusion: Our data
indicate that in vivo intrahepatic electroporation-mediated gene transfer of AAT is a safe and efficient
procedure resulting in reduction of pulmonary emphysema in pallid mice.
Keywords: alpha1 antitrypsin; nonviral gene delivery; electroporation; localized gene delivery;
emphysema; liver gene transfer
1. Introduction
Alpha1 antitrypsin (AAT) deficiency, an autosomal codominant disease that is caused by mutation
of the SERPINA1 gene, leads to liver and lung disease. The prevalence of AAT deficiency varies
considerably, yet it is estimated that 3 million people carry allele combinations that are associated
with severe deficiency [1]. Three major AAT variants (PI*M, PI*Z, and PI*S) are reported; of these,
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PI*Z is the most common and is associated with poor prognosis [2]. In AAT deficiency, there is
either reduced or no secretion of AAT in circulation from liver cells. Individuals with AAT deficiency
usually develop symptoms of lung involvement at older ages, which include shortness of breath,
chronic bronchitis, high prevalence of bronchial obstruction with Forced expiratory volume FEV1
decline, and an ongoing decrease of computer tomography CT lung density that reflects progressive
emphysematous lung destruction [3]. The dogma by which AAT deficiency is primarily a Caucasian
disease has been disputed by a detailed epidemiological study [1]. Indeed, an increasing number of
cases is reported for African, Asian, and Middle Eastern populations, rendering AAT deficiency a
global concern. Furthermore, carriers of the alleles are at high risk of developing severe disease due to
increased air pollution [4].
Current therapeutic options are comprised of lung or liver transplantation, or life-long intravenous
weekly augmentation therapy with commercially available affinity-purified plasma-derived human
AAT [5]. Lung or liver transplantations are associated with technical and immunological complications,
and both exert high financial burden [6]. Therapeutic options that can provide sustained levels
of circulating AAT for prolonged periods of time are therefore needed. In its present form, AAT
augmentation therapy requires weekly intravenous administration of AAT, thus reducing quality of
life. Moreover, affinity-purified AAT is a blood product and its quantities are limited on a global scale.
In addition, there is the issue of nonphysiological pharmacokinetics of infused AAT: circulating levels
spike for a day and then rapidly decline, exhibiting a half-life of 4.5 days followed by almost 3 days of
very low levels of AAT. This is in contrast to the physiological plateau-like liver-derived circulating
levels of AAT, which is apparently superior to pulse-like AAT infusions in as far as tissue protection
by AAT [7]. Gene therapy offers an opportunity to provide sustained levels of AAT, with possible
therapeutic benefit and greater patient compliance.
Clinical trials for using gene therapy in AAT deficiency have been running for longer than the past
decade since the condition is a well-recognized one-gene disease. Two trials used Adeno-Associated
Virus (AAV), while the third trial used nonviral cationic liposomes [7]. AAV was injected intramuscularly,
while liposomes were administered as droplets in the nostrils. Both of these vectors are limited due to
dose-dependent toxicity and low transgene expression levels and rely on nonphysiological extrahepatic
production of AAT. Thus, a more relevant and feasible approach for achieving gene transfer is required.
In vivo electroporation-mediated gene transfer is based on the application of short electric pulses.
This method has been shown to be effective in various disease models [8–11] and has recently been
applied in clinical practice [12]. While the main source of native AAT is the liver, most other studies
have focused on gene delivery for systemic distribution (e.g., muscle tissue) or in a lung-directed
manner [7].
In the current study, the outcomes of electroporation-mediated AAT gene therapy in the liver is
tested in mice that carry a mutation in the pallid gene. The pallid mutation hinders normal secretion
of AAT in circulation, leading to spontaneous development of pulmonary emphysema [13]. We thus
evaluated clinically relevant outcomes of in vivo intrahepatic electroporation-mediated AAT gene
delivery in this model.
2. Materials and Methods
2.1. Plasmid
Plasmids pEF-AAT carrying the complete human SERPINA1 into pEF (plasmid with eukaryotic
translation elongation factor 1 alpha 1 promotor region), containing the Epstein barr virus sequence
and human gene (SERPINA1) encoding1-antitrypsin (AAT) as described by Stoll SM et al. [14], was
used for this study. The plasmid consists of full SERPINA1 on a 19-kb genomic fragment and the
Epstein Barr Virus (EBV) gene EBNA1. For large-scale plasmid production, we used the Giga prep kit
(Qiagen, Germantown, MD, USA) following manufacturer’s protocol. For electroporation, the plasmid
was diluted in distilled water to a concentration of 1 µg/µL.
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2.2. Pallid Mice
C57BL/6J-backcrossed pallid mice (pa/pa) were obtained from the laboratory of G Lungarella
(University of Sienna, Sienna, Italy). The mice were housed in an environment controlled for light (7 am
to 7 pm) and temperature (18 ◦C to 22 ◦C); food (Mucedola Global Diet 2018; Harlan, Corezzana, Italy)
and water were provided for consumption ad libitum. Experiments were performed in accordance
with the standards of the European Convention of Animal Care. The study protocol was approved by
the Animal ethics committee Canton Bern and by the University of Bern Animal Study Committee (BE
56/15, date: 17 May 2016).
Pallid mice (10–12 months old, female) were studied. Animals were randomly divided into three
groups: (a) no treatment (Pa/Pa), (b) empty vector electroporation (empty vector), and (c) pEF-AAT
plasmid (AAT plasmid) electroporation, n = 5 in each group. Electroporation-mediated pEF-AAT or
empty vector was performed twice at days 0 and 15 after the first procedure. Animals were sacrificed
after day 30 from the first electroporation. Age- and gender-matched wildtype C57BL/6J mice served
as controls (wildtype, WT) (n = 5).
3. Electroporation-Mediated Gene Transfer to the Liver
Mice were injected with buprenorphine (0.1 mg/kg) subcutaneously 30 min before surgery.
For anaesthesia, mice received midazolam (Dormicum) 5 mg/kg, medetomidine (Domitor) 0.5 mg/kg,
and fentanyl (Fentanyl-Janssen) 0.05 mg/kg intraperitoneally. For eye protection, bepanthen (5%
Dexpanthenol) was applied to the eyes. For the electroporation procedure, sterile conditions were
applied. The fur from the abdominal area was shaved, and the skin was disinfected using betadine
(Mundipharma, Basel, Switzerland). A midline incision was performed, and the liver was mobilized
using cotton sticks. The caudate lobe was pulled, and 50 µL of plasmid (empty vector or pEF-AAT
(1 µg/µL)) was injected using an insulin syringe (BD Ultrafine 6 mm, BD biosciences, San Jose, CA, USA).
Immediately thereafter, the tweezer electrode (1 cm × 1 cm) was placed directly over the injected area
and electroporation was performed using super electroporator NEPA 21 type II (NEPAGENE Ltd.,
Chiba, Japan) ×8 pulses of 200 v/cm of 10 millisecond duration at intervals of 50 milliseconds of poring
pulses and ×8 pulses of 200 v/cm of 50 millisecond duration at 50 millisecond intervals of transfer
pulses, following the optimized parameters as described before [15]. After electroporation, the liver
was carefully pushed back into place using cotton sticks and the abdomen was stitched closed by
two layers using absorbable 4-0 silk suture (Ethicon, Cincinnati, OH, USA). Mice were allowed to
recover while receiving intraperitoneal atipamazol (Revetor) 2.5 mg/kg, naloxon (Narconti) 1.2 mg/kg,
and flumazenil (Anexata) 0.5 mg/kg. Buprenorphine (0.1 mg/kg) was administered for 3 days after
surgery. An appropriate score sheet was maintained to monitor the well-being of the mice.
4. Assessment
4.1. Lung Function
Mice were anaesthetized with a mixture of midazolam (5 mg/g), fentanyl (50 µg/g), and
medetomidin (0.5 µg/g), were intratracheally intubated, and were connected to a computer-controlled
small animal ventilator (flexiVent, SCIREQ, Montreal, Canada) at a frequency of 120 breaths/min and
tidal volume of 10 mL/kg. After stabilization, lung mechanics were measured at positive end-expiratory
pressure (PEEP) levels of 3 cm H2O. A pressure volume (PV-P) perturbation was performed to collect
lung mechanic data, i.e., static compliance; A- and K-factor of the Salazar–Knowles equation; and area,
i.e., the amplitude of the hysteresis prior to PV loop.
4.2. Tissue Collection
After lung function assessments, the animal was sacrificed. Bronchioalveolar lavage, blood, and
lung and liver tissue were collected for further analysis.
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4.3. Histology and Microscopy
Paraffin-embedded lung sections were stained with haematoxylin and eosin (H&E).
For stereological analysis, images were acquired using ColorView IIIu digital camera (Olympus Soft
Imaging Solutions, Münster, Germany) on a Leica DM RB light microscope (Leica, Wetzlar, Germany)
equipped with an automated motorized stage at magnification of ×20. For overviews, the images
were acquired by Pannoromic 250 II flash scanner (3D HISTECH Ltd., Budapest, Hungary) at ×20
magnifications. Immunofluorescence images were acquired using LSM 710 confocal microscope (Zeiss,
Ulm, Germany).
4.4. Stereological Analysis
Stereological measurements were performed in compliance with the standards for quantitative
assessment of the American Thoracic Society (ATS) and European Respiratory Society ERS [16].
Immediately after lung function evaluation, the animal was sacrificed and the left lung was prepared
for stereological analysis. The left lobe was inflated with paraformaldehyde 4% at a pressure equivalent
to 20 cm H2O; when completely expanded, the trachea was ligated and stored in 4% paraformaldehyde
for histological experiments. Left lung volume was determined by the water-displacement method [17];
fixed lungs were embedded in 2.5% agar and cut in transverse slices of 1.2 mm. About 6–9 pieces were
obtained and paraffin-embedded; 5-µm sections were stained with H&E. One hundred micrographs
were captured for each animal using a ColorView IIIu digital camera (Olympus Soft Imaging Solutions)
on a Leica DM RB light microscope equipped with an automated motorized stage at a final magnification
of ×20. Images were quantitatively analysed using a test system of points and lines superimposed
over the digital images via the STEPanizer (software designed by Stefan Tscahnz, University of Bern,
Bern, Switzerland) [18]. Point counts yielded relative volume densities and were categorized as outside,
artefacts, septa, infiltrated septa, or nonparenchyma. Parenchymal air space proportion was calculated
by subtracting points falling on septa from all points hitting the parenchyma. Absolute volumes of air
spaces and septa were computed by multiplying volume densities by absolute lung volume [19,20].
Mean linear intercept and septal surface area were calculated using line counts intersecting septa and
by multiplying by lung volume. The right lobes of the lung were ligated at the right bronchus and
snap-frozen for RNA/protein extraction in Tissue teck OCT (Optimal cutting temperature compound)
(Shakura Finetek, Alphen aan den Rijn, Netherlands).
4.5. Sirius Red Staining
Liver tissue was cryopreserved using Tissue-tec OCT compound (Genprice Inc. San Jose, CA, USA),
and 10-µm cryosections were stained with Sirius Red staining (Sigma Aldrich, USA) to evaluate the
effect of electroporation on liver collagen according to the manufacturer’s instructions.
4.6. Immunofluorescence Staining
Cryosections were fixed with 70% ethanol, washed with 1×PBS thrice, and incubated with primary
antibody recombinant anti-alpha1 antitrypsin antibody (Abcam, Cambridge, UK) at a dilution of 1:100
overnight at 4 ◦C. After the 1 × PBS wash, the slides were treated with Fluorescein isothiocyanate
(FITC) (anti-rabbit) secondary antibody at a dilution of 1:1000 and were incubated in a moist chamber
for 2 h at room temperature; the slides were washed with 1 × PBS and mounted using the glycerol
mounting media-anti fade with (4′,6-diamidino-2-phenylindole) DAPI (Abcam, Cambridge, UK). Zeiss
LSM 710 (Karl Zeiss, Ulm, Germany) confocal microscope was used for visualization.
4.7. Liver Homogenization
Liver was resected and frozen in liquid nitrogen; 100 mg of frozen liver was homogenized in
100 uL protein lysis buffer (Pierce Lysis buffer, Thermo-Fischer Scientific, Waltham, MA, USA) and
homogenized using polytron for 20 s. The homogenate was centrifuged at 12,000 rpm for 20 min to
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remove debris. The cleared lysate was used for further analysis. Total protein was measured using the
standard Bradford method (BioRad, Irvine, California, USA).
4.8. ELISA
Human AAT was measured in the serum and in the liver homogenate of mice using Human
A1AT ELISA kit (ICLLAB, Portland, OR, USA), and mice AAT in the liver homogenate of mice was
measured using the mouse alpha1 antitrypsin ELISA kit (Abcam, Cambridge, UK) following the
protocol provided.
4.9. Myeloperoxidase Activity
Activity of neutrophil-specific myeloperoxidase enzyme (MPO) was measured by an adaptation
of the method described by Bradley et al. [21] and modified by Mullane et al. [22]. MPO activity was
measured in bronchioalveolar lavage BAL fluid. The sample was mixed with o-dianisidine, and the
reaction was started by adding H2O2. The reaction was then stopped by addition of NaN3 solution
after 3 min of incubation, and optical densities (ODs) were measured at 450 nm. To quantify MPO
activity, a standard curve was obtained. MPO values are expressed as mg/mL.
4.10. Measurement of Liver Injury
Serum samples were collected to assess the extent of liver injury after electroporation-mediated
gene transfer using enzymatic assays to measure albumin, ALT (alanine aminotransferase), and AST
(aspartate aminotransferase) (P800; Modular Analytics EVO, Roche, Mannheim, Germany).
5. Statistics
Data are presented as mean ± SD. We used one-way ANOVA and multiple comparison test or
unpaired t test using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). Results were
considered significant at p < 0.05.
6. Results
Human AAT is detected in the liver and sera of mice 30 days after intrahepatic
electroporation-mediated AAT gene transfer.
In order to characterize the production of human AAT after electroporation-mediated DNA
delivery to the liver, pallid mice underwent the procedure with either an empty vector or a pEF-hAAT
plasmid; for controls, wildtype mice and pallid mice were included in data collection (n = 5 per group).
As shown (Figure 1), human AAT production was readily detected 30 days after human AAT gene
transfer, as determined in liver homogenates (4463 ± 1356 pg/mg protein) and sera (75 ± 3.4 pg/mL)
(Figure 1a). Human AAT was undetectable in the control groups. Accordingly, immunofluorescent
staining depicted the expression of hAAT by mice liver cells with the anticipated cytoplasmatic
distribution of the protein (Figure 1b). Interestingly, mice AAT levels measured in liver did not show
any change among the different groups (data shown in the Supplementary Materials (Figure S1)).
6.1. Lung Function Is Improved after Intrahepatic Electroporation-Mediated AAT Gene Transfer
In order to examine whether AAT gene transfer has an impact on lung function, we measured
basal lung functions in mice (Figure 2). High lung tissue compliance indicates a lung with low elastic
recoil, typical in mice that develop emphysema. As shown (Figure 2a), static compliance (Cst) was
higher in pallid mice compared to wildtype (C57BL/6J) mice as well as to pallid mice transfected with
an empty vector. However, 30 days after AAT gene transfer to pallid mice, Cst was reduced to the
level of wildtype mice. Similarly, compliance under mechanical stress (Figure 2b), a measurement
of total lung capacity (i.e., A-factor), was higher in pallid mice compared to wildtype mice, agreeing
with the presence of pulmonary emphysema. Pallid mice displayed a significant reduction in lung
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capacity after AAT gene transfer, depicting values in the range of healthy wildtype mice. Estimating
atelectasis that exists before the PV loop, hysteresis was higher in pallid mice compared to wildtype
mice; however, after AAT gene transfer, it was reduced towards the range observed in healthy wildtype
mice (Figure 2c). Consistent with these results, pallid mice exhibited an upward and leftward shift in
PV relation compared to wildtype mice and compared to mice receiving AAT gene transfer; significant
differences were found in the area between the inflation and deflation limb of the PV curves (Figure 2d,e)
and in the shape constant k that describes the curvature of the PV loop curves (Figure 2f). This indicates
that treatment with AAT gene therapy changed the intrinsic elastic properties of the respiratory system.
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transfer as observed by Ishak system staining [23]. Wildtype (f), pallid (g), empty vector (h), and 
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Figure 2. Lung function in pallid mice after intrahepatic electroporation-mediated hAAT gene transfer.
Respiratory parameters were performed on a flexiVent system (SCIREQ): static co pliance, total lun
capacity, and hysteresis were obtained in tracheotomize mice. B6, C57BL/6 mice; Pa, pallid mice; EV,
pallid mice tre ted with an empty vector; AAT, pallid mic treated with AAT plasmid (n = 5 per
group). Lung function measurements: (a) static compliance, (b) total lung c pacity, and (c) hysteresis
(area unde the (pressure volume) PV loop). Static compliance was calcula ed from the deflati g
part of th PV loop between 3–7 cm H2O, total lung capacity was measured using a deep inflation
manoeuvre, and hyster sis represents th area between the inflating and deflating parts of the PV loop.
Each symbol represents the averag of th e correct manoeuvres p r mouse. V lues re shown as mean
± SD; * p < 0.05, *** p < 0.001 compared to untr ated cont ol group. (d) Pr ssure-volu e (PV) loop ,
(e) analysis of th PV-loops, and (f) parameter K representing the curvat re of he PV lo ps curves:
Two-way ANOVA applying Bonferroni’s multiple comparisons test com ed th mean inspiratory
volume of four groups (used at each pressure step up to 30 cm H2O). Statistical significanc * p < 0.05.
t-test were used in B and C. Values are express d as mean and ± SD * p < 0.05, *** p < 0.001 compared
to the untre ed ontrol group.
Table 1. Parameters for the lung function test (Figure 2): data are presented as mean ± SD.
Parameters WT (Wildtype) Pallid Mice Empty Vector hAAT Plasmid
Static Compliance (mL/cmH2O) 0.068 ± 0.004 0.0767 ± 0.004 0.0749 ± 0.001 0.064 ± 0.002
Total Lung capacity (A) (mL) 0.80 ± 0.04 0.95 ± 0.03 0.99 ± 0.06 0.73 ± 0.01
Hysteresis (cmH2O/mL) 3.29 ± 0.34 4.70 ± 0.31 5.50 ± 0.13 3.66 ± 0.40
AUC (area under curve)
(mL/cmH2O)
0.39 ± 0.06 0.72 ± 0.10 0.73 ± 0.11 0.47 ± 0.06
k (curvature of the upper portion
of the deflation limb of the
pressure volume (PV) curve)
0.11 ± 0.006 0.13 ± 0.004 0.143 ± 0.0005 0.12 ± 0.004
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6.2. Stereological Analysis Reveals Improved Lung Architecture after AAT Gene Transfer
Histological evaluation of the lungs of pallid mice at 12 months of age revealed the presence of
emphysema, characterized by an enlargement of the distal airspaces and loss of the normal alveolar
structures as compared with wildtype mice (Figure 3a,b). An evident reduction of alveolar space
enlargement was observed in the distal zones of the lung of pallid mice after AAT gene transfer as
compared to mice treated with an empty vector (Figure 3c,d). Surface area density and mean linear
intercept LM values of pallid mice at 12 months reflect a loss of alveolar tissue in the lung parenchyma.
These changes are not evident in mice treated with AAT gene therapy compared to the mice treated
with control plasmid (Figure 4a,b). Values are shown in Table 2. Additional data is presented in the
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Figure 3. Left lobe lung histology after intrahepatic AAT gene transfer by electroporation in vivo:
Representative micrographs of the lungs of animals from different groups. (a) Normal lung from
wildtype (WT) (C57BL/6J) mice, (b) air space enlargement visible in the non-transfected pallid mice
and (c) in the animals treated with empty vector, (d) animals treated with the pEF-AAT plasmid:
×20 magnification, scale bar 500 µm. Inset, images at higher magnification as indicated by dashed
frame (digital zoom; scale bar 200 µm).
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Figure 4. Lung morphometry: (a) septal surface area and (b) mean linear intercept (LM) in different
experimental groups, as indicated. For each animal, the left lobe was nalysed, and all parameters
relate to this specific lobe. Statis ical valu s are expressed as mean ± SD, u pair t test was performed,
and ach group was ompared to each other. * p < 0.05, ** p < 0.01.
Table 2. Parameters for stereology (Figure 4): data are presented as mean ± SEM.
Parameters WT Pallid Mice Empty Vector hAAT Plasmid
Surface Area (cm2) 238.2 ± 22.76 187.6 ± 8.43 154.4 ± 16.09 229.6 ± 7.94
Mean liner intercept (LM) (µM) 40.9 ± 1.68 52.38 ± 1.42 58.68 ± 3.69 45.79 ± 0.33
6.3. AAT Gene Transfer by Electroporation Did Not Induce Liver Injury
The effect of electroporation on liver function was assessed by measuring serum AST (Figure 1c),
ASL (Figure 1d), and albumin (Figure 1e); all values were within the normal range as shown before [24].
Moreover, Liver cryosections were stained for evaluation of collagen by Sirius red staining and observed
under the microscope for Ishak system staining [23]; no signs of fibrosis were detected in any group
(Figure 1f–i).
6.4. Lung Neutrophil Burden Is Reduced after AAT Gene Transfer
Neutrophil activity was depicted by measuring MPO levels (Figure 5). The baseline MPO in
wildtype mice was 0.114± 0.032 mg/mL. However, MPO activity in pallid mice was 0.220± 0.050 mg/mL
and that in animals treated with an empty vector was 0.287 ± 0.085 mg/mL; in contrast, after AAT gene
transfer, MPO levels were significantly reduced to 0.147 ± 0.040 mg/mL (p < 0.05).
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Figure 5. Bronchioalveolar lavage (B L) fluid neutrophilic activity: fter electroporation-mediated
hAAT gene transfer, myeloperoxidase assay ( P ) as perfor ed to assess the neutrophil activity
in BAL fluid. ata are sho n as ean S , n aired t test as performed, and each group was
compared to each other * p 0.05, ** p 0.01.
7. Discussion
The present study provides evidence that in vivo intrahepatic electroporation-mediated AAT
gene transfer improves lung function and morphology and reduces neutrophil activity in a mouse
strain that models human AAT deficiency, i.e., pallid mice.
Gene therapy has been tested for AAT deficiency in preclinical studies using various animal models
and using either viral vectors [25–29] or nonviral vectors, e.g., liposomes [30–32]. For clinical trials,
however, different serotypes of AAV have been used [33,34] by either intramuscular or intrapleural
routes. Aside from the disadvantages of viral interventions or intrapleural delivery profiles, AAT is
primarily synthesized by hepatocytes, which hold inherent and optimal processing steps for secretion
of mature AAT. Circulating AAT provides systemic tissue protection, predominantly in the form of a
superior balance between protease and antiprotease activities as well as protection of lung tissue from
excessive neutrophil elastase activity. Therefore, targeting the liver for gene transfer would be a more
physiological choice.
Gene therapy that is ai e at chronic iseases oul benefit fro persistent gene expression,
requiring a promoter that is preferably cell specific and holds extrachromosomal replication mechanisms
for prolonged expressi n. In the curr nt study, we introduc d a h man hepatocyte-directed pEF-AAT
plasmid directly to the liver by applying in vivo electroporation-mediated gene transfer. The animals
survived the proc ur with no complicatio s, s erting the safety of in vivo electroporation for
the liver [15,35] and possibly ther o gans [8–11,36]. The issue of organ distri uti n of the plasmid
deserves further exploration, w th he g al of developing a m thod whereby a larger area of liver can
be intr duced wi a plasmid.
In a recent phase 2a clinical trial, AAV was injected intramuscularly and result d in elevated levels
of circulating AAT in 3 out of 9 patients for a period of 5 years [37]. Despite these promising re ults,
it i not clear what d to increased tolerogenic resp nses in the positive producers. Nonetheless,
the advantage of a non iral electroporation method is the lack of an immune provo ati n which should
theref re be tested in the clinical setup in the futur .
In the current st , e de str te i r e l f cti i a i als receiving intrahepatic
electroporation-mediated A T gene transfer. In untreated animals, reduced static compliance parameter
showing lung expandability, reduced inspiratory capacity, and reduced hysteresis as a measure of
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atelectasis were observed. Compared to these findings, the PV loop showed a downward shift in the
animals receiving AAT gene transfer. Also, the lung architecture showed a trend towards improvement,
and most importantly, no further structural deterioration was observed after electroporation-mediated
AAT gene transfer.
The current study is not without limitations. The procedure of in vivo electroporation is invasive,
and minimally invasive methods need to be applied that can target the liver. One possibility might
be the application of electrospray [38], a method that relies on the principle of columb repulsion and
can be delivered using single port device. In addition, the experimental endpoint was collected one
month after the first treatment; a long-term study is warranted to see the prolonged effect of this
approach. Also, at this proof-of-concept stage of study, we did not fully explore options for increasing
the levels of human AAT in circulation. The relatively low levels of circulating human AAT under
the presently studied settings may be the result of several limitations: (1) the mice could generate
antihuman antibodies against human AAT; (2) the pallid mutation could interfere with AAT secretion;
(3) dynamics of plasmid expression might reveal suboptimal production of human AAT on day 30
as per the present report, and (4) volumes and doses of plasmid administration should be further
explored. Nonetheless, the fact that the outcome of the described gene delivery method resulted in
an altered profile of emphysema suggests that the levels measured on day 30 might be sufficient for
achieving a biologically relevant impact. Moreover, to further evaluate the effect of AAT gene transfer
on lung architecture, a long-term study will be needed specially as a prophylaxis and a gene transfer
procedure before emphysema starts to develop in pallid mice [39] should be performed.
8. Conclusions
In conclusion, intrahepatic electroporation-mediated AAT gene transfer is a feasible, safe, and
reproducible approach in the context of a mouse model of AAT deficiency with spontaneous pulmonary
emphysema. In addition to improved lung function, electroporation-mediated AAT gene transfer
effectively reduces local neutrophil activity. While the current study offers a good model for correction
of lung damage in AAT deficiency, a more elaborate preclinical study is required using large animal
models before clinical translation is considered.
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